Andreas Tebbe
Overview
Explore the profile of Andreas Tebbe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
560
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ducret A, James I, Wilson S, Feilke M, Tebbe A, Dybowski N, et al.
PLoS One
. 2019 Mar;
14(3):e0213892.
PMID: 30897176
Human protein biomarker discovery relies heavily on pre-clinical models, in particular established cell lines and patient-derived xenografts, but confirmation studies in primary tissue are essential to demonstrate clinical relevance. We...
2.
Roolf C, Dybowski N, Sekora A, Mueller S, Knuebel G, Tebbe A, et al.
Mol Cell Proteomics
. 2017 Apr;
16(7):1365-1376.
PMID: 28450419
Constitutively activating internal tandem duplication (ITD) alterations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) are common in acute myeloid leukemia (AML) and classifies FLT3 as an attractive...
3.
Langfelder P, Cantle J, Chatzopoulou D, Wang N, Gao F, Al-Ramahi I, et al.
Nat Neurosci
. 2016 Feb;
19(4):623-33.
PMID: 26900923
To gain insight into how mutant huntingtin (mHtt) CAG repeat length modifies Huntington's disease (HD) pathogenesis, we profiled mRNA in over 600 brain and peripheral tissue samples from HD knock-in...
4.
Tebbe A, Klammer M, Sighart S, Schaab C, Daub H
Rapid Commun Mass Spectrom
. 2015 Sep;
29(9):795-801.
PMID: 26377007
Rationale: Advanced implementations of mass spectrometry (MS)-based proteomics allow for comprehensive proteome expression profiling across many biological samples. The outcome of such studies critically depends on accurate and precise quantification,...
5.
Grundner-Culemann K, Dybowski J, Klammer M, Tebbe A, Schaab C, Daub H
J Proteomics
. 2015 Sep;
130:1-10.
PMID: 26361996
Non-small cell lung cancer (NSCLC) cell lines are widely used model systems to study molecular aspects of lung cancer. Comparative and in-depth proteome expression data across many NSCLC cell lines...
6.
Gundisch S, Grundner-Culemann K, Wolff C, Schott C, Reischauer B, Machatti M, et al.
J Proteome Res
. 2013 Aug;
12(10):4424-34.
PMID: 23984901
Protein phosphorylation controls the activity of signal transduction pathways regulated by kinases and phosphatases. Little is known, however, about the impact of preanalytical factors, for example, delayed times to tissue...
7.
Oppermann F, Klammer M, Bobe C, Cox J, Schaab C, Tebbe A, et al.
J Proteome Res
. 2013 Aug;
12(9):4089-100.
PMID: 23898821
Advances in mass spectrometric methodology and instrumentation have promoted a continuous increase in analytical performance in the field of phosphoproteomics. Here, we employed the recently introduced quadrupole Orbitrap (Q Exactive)...
8.
Fratelli M, Fisher J, Paroni G, Di Francesco A, Pierri F, Pisano C, et al.
Eur J Cancer
. 2012 Dec;
49(6):1491-500.
PMID: 23245330
ST1926 is an atypical retinoid and a promising anti-tumour agent with selective apoptotic activity on the leukaemic blast. The anti-tumour activity of the compound has been associated with its capacity...
9.
Weigand S, Herting F, Maisel D, Nopora A, Voss E, Schaab C, et al.
Cancer Res
. 2012 Jul;
72(17):4329-39.
PMID: 22777824
The cell surface glycoprotein CD44 plays an important role in the development and progression of various tumor types. RG7356 is a humanized antibody targeting the constant region of CD44 that...
10.
Klammer M, Kaminski M, Zedler A, Oppermann F, Blencke S, Marx S, et al.
Mol Cell Proteomics
. 2012 May;
11(9):651-68.
PMID: 22617229
Targeted drugs are less toxic than traditional chemotherapeutic therapies; however, the proportion of patients that benefit from these drugs is often smaller. A marker that confidently predicts patient response to...